Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

(2020) Changhai Lei et al.   Nature Communications

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

(2020) Yadi Zhou et al.   Cell Discovery

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

(2020) Mark Roschewski et al.   Science Immunology

Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection

(2020) Jin Wei et al.   CELL

Chemotherapy and COVID-19 Outcomes in Patients With Cancer

(2020) Justin Jee et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug repurposing approach to fight COVID-19

(2020) Thakur Uttam Singh et al.   Pharmacological Reports

Human recombinant soluble ACE2 in severe COVID-19

(2020) Alexander Zoufaly et al.   Lancet Respiratory Medicine

Outcomes of COVID-19 Patients under Cytotoxic Cancer Chemotherapy in Brazil

(2020) Mateus Bringel Oliveira Duarte et al.   Cancers

The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations

(2018) Alexandra B. Keenan et al.   Cell Systems

Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis

(2014) Jason Kindrachuk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection

(2014) Julie Dyall et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY